Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory chain

Fig. 4

CHCHD4 promotes mitochondrial ROS production in response to CI inhibitors. a Graph shows dose-response curve of whole CI activity in the presence of rotenone (black line) and BAY 87-2243 (blue line), using a 10-fold dilution series (top concentration 50 μM). b Graph shows relative growth of control U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1, WT.cl3) and CHCHD4 (C66A/C68A)-expressing cells incubated for 72 h in the absence or presence of BAY 87-2243 using a 2-fold dilution series (top concentration, 100 nM). Data are presented as BAY 87-2243-treated relative to untreated (0 h). n = 3, mean ± SD. *p < 0.05. c Images of cells described in b, either untreated (NT) or treated with of BAY 87-2243 (5 nM) for 3 h, in the absence (−) or presence (+) of the ROS scavenger Trolox (100 μM). MitoSOX Red ROS indicator (5 μM) was added for 30 min prior to live cell imaging by fluorescence microscopy. d Graph shows the percentage of the mean fluorescence intensity quantified from images of cells described in c, which were either untreated (NT) or treated with BAY 87-2243 (5 nM), or with BAY 87-2243 (5 nM) and Trolox (100 μM) (BAY + Trolox) for 3 h. MitoSOX Red ROS indicator (5 μM) was added for 30 min prior to live cell imaging by fluorescence microscopy. n = 5 images per condition, mean ± SD, n.s. not significant, *p < 0.05, **p < 0.01. e Graph shows the percentage of the growth of cells treated without (−) or with (+) BAY 87-2243 (5 nM) for 24 h, in the absence (NT, black bars) or presence of Trolox (100 μM) (blue bars). Data are represented as the percentage of the growth of cells. n = 3, mean ± SD. n.s. not significant, *p < 0.05, **p < 0.01

Back to article page